XRPD is a primary tool for phase identification, crystallinity, polymorph control, and quantitative solid-mixture analysis.
This decision-focused guide explains the scientific measurement basis, when to use it, its limitations, sample amount considerations, competing methods, FDA-facing concerns, and common mistakes.
XRPD measures how X-rays scatter from ordered atomic planes in a crystalline solid. The positions and intensities of diffraction peaks provide a phase fingerprint and can also support unit-cell indexing, crystallinity assessment, quantitative phase analysis, and non-ambient studies.
Use XRPD for polymorph identification, hydrate/solvate monitoring, crystallinity checks, lot comparison, drug-product residual-solid analysis, mineral/phase identification, and release or stability methods where the crystal form is the quality attribute.
XRPD is weaker for amorphous materials, very low-level phases, highly preferred orientation, severe peak overlap, small amounts in excipient-rich matrices, and cases where two forms are structurally similar. It often needs Raman, IR, DSC, ssNMR, microscopy, or chromatography as orthogonal evidence.
Exact amount depends on holder, geometry, concentration, and detection limit. Sample matrices may include large or small solids, liquids, suspensions, powders, and films; for material-limited projects, scope should be confirmed before shipment.
Raman, FTIR, solid-state NMR, DSC/TGA, microscopy, MicroED, and SCXRD can compete or complement XRPD depending on whether the question is phase identity, structure, thermal behavior, molecular environment, or morphology.
FDA cares that the method is specific for the relevant form in the real matrix, that sample preparation does not convert the form, and that validation or verification supports the intended release, stability, comparability, or CMC decision under ICH Q2(R2)/Q14 principles.
Common mistakes are treating a single ambient scan as a stability study, ignoring humidity/temperature history, overinterpreting minor peak differences, failing to test residual solids after dissolution, and not proving specificity against realistic polymorph, hydrate, solvate, and excipient interferences.
Triclinic uses diffraction and crystallographic analysis to solve real-world solid-form problems involving polymorphs, salts, cocrystals, hydrates, solvates, crystallinity, amorphous content, and phase changes during processing or storage. The work is applied to form selection, patent support, stability risk, formulation troubleshooting, and quality investigations where the arrangement of molecules or phases controls material behavior.
The table below lists the specific platforms, brands, models, software, detectors, and capability notes relevant to this service area.
| Instrument or platform | Brand, model, software, or detector | Additional capabilities and use |
|---|---|---|
| Powder X-ray diffraction | Rigaku SmartLab instruments; quadruple-redundant PXRD capacity; Cu source; 1D and 2D, reflection and transmission orientations | Phase identification, crystallinity, quantitative/semi-quantitative phase analysis, texture/microstructure, tablets, powders, thin films, and drug-product mapping. |
| Photon-counting 2D detection | Rigaku HyPix-3000 detector | High-count-rate, fast-readout, essentially no-noise photon-counting detection for advanced diffraction studies. |
| VT/VRH-PXRD environment | Anton Paar CHCplus Cryo and Humidity Chamber with liquid-nitrogen cooling | 2-95% RH, multiple temperature windows, vacuum/air/inert atmospheres, and program-controlled or continuous VT/VRH collection strategies. |
| cGMP and non-GMP PXRD capacity | Four powder X-ray diffractometers; three cGMP and one non-GMP system with 2D detector | Routine release/validation-ready XRPD plus advanced variable-temperature, variable-humidity, and 2D materials studies. |
| MicroED structure determination | ELDICO ED-1 MicroED system | Unit-cell and crystal-structure determination from nanocrystalline material when suitable single crystals are unavailable. |
| SCXRD / synchrotron access | Single-crystal X-ray diffraction and synchrotron-access workflows | Definitive crystal structures, indexing, molecular conformation, packing, salt/cocrystal assignment, and patent-support studies. |
This example shows why diffraction is often more useful when the experiment recreates a stress condition rather than relying on a single ambient scan. Variable-temperature and variable-relative-humidity XRPD can track how a crystalline material responds as heat and humidity change, which is directly relevant to hydrate/anhydrate control, polymorph risk, process excursions, and stability investigations.
These examples include technical resources, regulatory guidances, or literature relevant to the technique. Download buttons are placed at the bottom-left of each example.
Author: Triclinic Labs
Publication date: 2023
Abstract: Application note showing how VT/VRH-PXRD follows theophylline phase transitions under controlled humidity and temperature. The example supports using non-ambient diffraction to evaluate hydrates, anhydrates, stability boundaries, and process-relevant phase transformations.
Author: Triclinic Labs
Publication date: 2023
Abstract: The XRPD FAQ explains why crystalline materials give distinctive diffraction fingerprints, how peak positions and intensities support phase identification, and why experimental details and sample handling affect interpretation.
Author: International Council for Harmonisation / FDA
Publication date: 2024
Abstract: FDA notes that ICH Q2(R2) and Q14 describe validation and development principles for analytical procedures used to assess drug substance and drug product quality. These guidances frame FDA expectations for specificity, accuracy, precision, range, robustness, lifecycle management, and fit-for-purpose method evidence.
Use this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View technique
Tell Triclinic what sample you have, what decision the data must support, what prior data are available, and whether cGMP, release, validation, or regulatory documentation is required.
